The Cell and Gene Therapy (CGT) Area has gained traction in recent years. A majority of big pharma has CGT assets in their pipeline. While it has a strong pipeline, the area witnessed a continued flow of investment. In our latest industry report on Cell and Gene Therapy Sector Performance and Outlook, we discuss how and why we believe that the CGT area has a lot to offer and except to see continued growth.
Deal making in the global healthcare industry has been relatively slow in 2022, compared with a blockbuster 2021. Investors were primarily forced to hold off on deal making because of the uncertainty regarding the global growth outlook.
The increased demand on healthcare services will be compounded by the apparent increased risk of infection among healthcare workers.
According to the International Monetary Fund, the recession triggered by the pandemic will likely be “way worse” than the 2008–09 global financial crisis.
Active collaboration between intellectual property (IP) and Research and Development (R&D) teams is critical for innovation to thrive as well as to reduce legal risks.
The Covid-19 pandemic has exposed glaring fault lines in the medical care infrastructure, and in emergency health response systems around the globe.
Data & Analytics
Data Engineering & Cloud
Customer Insights
Competitive & Market Intelligence
Marketing & Sales Enablement
Strategy & Planning
Supply Chain
R&D & Innovation
Intellectual Property
Pricing
ESG
Lending Services
Investment Banking Advisory
Financial Risk
Nonfinancial Risk
Investment Research
+ View All Solutions
Financial Institutions
Investment Banks
Corporate & Commercial Banks
Asset & Wealth Management Firms
Private Equity & Venture Capital Firms
Corporates
Technology & Telecom
Life Science & Healthcare
Manufacturing & Industrial Goods
Energy
Chemicals
CPG & Retail
Logistics & Transportation
Development Sector Practice
Professional Services Firms
Consultancy & Advisory Firms
Legal Firms
Real Estate Firms
Education & EdTech Firms
© 2022 Evalueserve. All rights reserved.
